Form 4: Corcept Therapeutics Officer Lyon Exercises Stock Options and Sells Shares
SEC Form 4 Filing
Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on May 2, 2024, according to a recent SEC filing.
Summary
- On May 2, 2024, Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options to acquire 10,830 shares of common stock at a price of $11.35 per share.
- Simultaneously, Lyon sold 10,830 shares of common stock at $26 per share.
- Following these transactions, Lyon directly owns 7,314 shares of Corcept Therapeutics common stock, which includes 2,739 shares underlying unvested restricted stock awards.
- The sale was conducted under a pre-arranged 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports transactions. The use of a 10b5-1 plan suggests pre-planned activity, reducing potential negative interpretations.
Industry Context
Insider transactions are routinely monitored and reported to the SEC. The use of 10b5-1 plans is a common practice to allow insiders to sell shares without being accused of trading on non-public information.
Key Dates
| Date | Description |
|---|---|
| 02/08/2029 | Expiration date of the stock options |
| 05/02/2024 | Date of stock option exercise and share sale |
| 05/06/2024 | Date of signature on the SEC filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.